{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT01757418",
            "nctIdAliases": [
                "NCT00644865"
            ],
            "orgStudyIdInfo": {
                "id": "09-06-172"
            },
            "secondaryIdInfos": [
                {
                    "id": "FD-R-005341-01",
                    "type": "OTHER_GRANT",
                    "domain": "FDA, OOPD"
                }
            ],
            "organization": {
                "fullName": "Albert Einstein College of Medicine",
                "class": "OTHER"
            },
            "briefTitle": "Intravenous Gammaglobulin for Sickle Cell Pain Crises",
            "officialTitle": "Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain",
            "therapeuticArea": [
                "Other"
            ],
            "study": "intravenous-gammaglobulin-for-sickle-cell-pain-crises"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2008-11"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2012-11-08",
            "studyFirstSubmitQcDate": "2012-12-21",
            "studyFirstPostDateStruct": {
                "date": "2012-12-31",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-09-29",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Deepa Manwani",
                "investigatorTitle": "Director, Sickle Cell Disease Program, Children's Hospital at Montefiore",
                "investigatorAffiliation": "Albert Einstein College of Medicine"
            },
            "leadSponsor": {
                "name": "Deepa Manwani",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine whether intravenous immune globulin is safe and effective in the acute treatment of pain crises in sickle cell disease.\n\nFunding Source: Food and Drug Administration (FDA), Office of Orphan Products Development (OOPD)",
            "detailedDescription": "Patients will be randomized to a single dose of IVIG versus normal saline placebo during an uncomplicated pain crisis. Length of VOC and other secondary endpoints will be monitored."
        },
        "conditionsModule": {
            "conditions": [
                "Sickle Cell Disease",
                "Pain"
            ],
            "keywords": [
                "Sickle Cell Disease",
                "Pain",
                "Immune Globulin"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 300,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Immune Globulin Intravenous",
                    "type": "EXPERIMENTAL",
                    "description": "IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.",
                    "interventionNames": [
                        "Drug: Immune Globulin Intravenous"
                    ]
                },
                {
                    "label": "Normal saline",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "An equivalent volume (weight-based)of normal saline",
                    "interventionNames": [
                        "Other: Normal saline"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Immune Globulin Intravenous",
                    "description": "A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.",
                    "armGroupLabels": [
                        "Immune Globulin Intravenous"
                    ],
                    "otherNames": [
                        "GAMUNEX (Talecris Biotherapeutics)"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Normal saline",
                    "description": "A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.",
                    "armGroupLabels": [
                        "Normal saline"
                    ],
                    "otherNames": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Length of vaso-occlusive crisis",
                    "description": "Length of vaso-occlusive crisis as measured from the time of presentation to the emergency room to end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge.",
                    "timeFrame": "Number of days from time of presentation to emergency room to end of crisis, average 4 days and maximum 30 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Total opioid use in equivalent of mg of IV morphine",
                    "description": "End of VOC end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge",
                    "timeFrame": "From study drug infusion to end of crisis, average 4 days and maximum 30 days"
                },
                {
                    "measure": "Time to end of vaso-occlusive crisis",
                    "description": "Time to end of vaso-occlusive crisis as measured from start of study drug infusion to end of VOC end of VOC defined as 12 hours from the last dose of parenteral opioid analgesia for the treatment of VOC prior to hospital discharge",
                    "timeFrame": "Number of days from start of study drug infusion to end of crisis, average 4 days and maximum 30 days"
                },
                {
                    "measure": "In vitro adhesion assays",
                    "description": "Activated Mac-1, Aged neutrophils",
                    "timeFrame": "Pre and 24 hours post study drug"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Documented diagnosis of sickle cell disease (SS or S-\u03b2 thalassemia genotype)\n* Age 12-65 years for Phase 1 (Completed), 6-13.99 years for Phase 2 (Ongoing)\n* Uncomplicated acute pain episode requiring hospital admission and parenteral narcotics\n\nExclusion Criteria:\n\n* Increased stroke risk as assessed by transcranial Doppler or magnetic resonance imaging (all subjects undergo testing)\n* Concomitant acute process, including fever \\> 38.5\u00b0 C with clinical suspicion of infection\n* Increased ALT \\> 2X ULN\n* Serum creatinine \u22651.3 mg/dL, \\>300 mg/dL protein in spot urinalysis, or known condition associated with renal dysfunction\n* Hb \\> 10 g/dL and Hct \\> 30%\n* Hb\\< 5 g/dl\n* Known IgA deficiency or known allergy to gamma globulin\n* Pregnancy or breastfeeding\n* Vaccination with a live attenuated virus in the preceding 6 weeks\n* Documented history of illicit (eg. heroin, cocaine) drug abuse or drug-seeking behavior\n* Current participation in another investigational drug study\n* Current treatment with chronic transfusion\n* Prior thromboses or current estrogen use",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Deepa G Manwani, M.D",
                    "role": "CONTACT",
                    "phone": "718-741-2342",
                    "email": "dmanwani@montefiore.org"
                },
                {
                    "name": "Karen Ireland",
                    "role": "CONTACT",
                    "phone": "718-741-2401",
                    "email": "kireland@montefiore.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Deepa G Manwani, M.D",
                    "affiliation": "Albert Einstein College of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Montefiore Medical Center",
                    "status": "RECRUITING",
                    "city": "Bronx",
                    "state": "New York",
                    "zip": "10467",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Deepa G Manwani, MD",
                            "role": "CONTACT",
                            "phone": "718-741-2342",
                            "email": "dmanwani@montefiore.org"
                        },
                        {
                            "name": "Deepa G Manwani, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84985,
                        "lon": -73.86641
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "17932253",
                    "type": "BACKGROUND",
                    "citation": "Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2008 Jan 15;111(2):915-23. doi: 10.1182/blood-2007-04-084061. Epub 2007 Oct 11."
                },
                {
                    "pmid": "14630831",
                    "type": "BACKGROUND",
                    "citation": "Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2004 Mar 15;103(6):2397-400. doi: 10.1182/blood-2003-07-2209. Epub 2003 Nov 20."
                },
                {
                    "pmid": "24857171",
                    "type": "RESULT",
                    "citation": "Shi PA, Manwani D, Olowokure O, Nandi V. Serial assessment of laser Doppler flow during acute pain crises in sickle cell disease. Blood Cells Mol Dis. 2014 Dec;53(4):277-82. doi: 10.1016/j.bcmd.2014.04.001. Epub 2014 May 21."
                },
                {
                    "pmid": "24052549",
                    "type": "RESULT",
                    "citation": "Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013 Dec 5;122(24):3892-8. doi: 10.1182/blood-2013-05-498311. Epub 2013 Sep 19."
                },
                {
                    "pmid": "25616042",
                    "type": "RESULT",
                    "citation": "Manwani D, Chen G, Carullo V, Serban S, Olowokure O, Jang J, Huggins M, Cohen HW, Billett H, Atweh GF, Frenette PS, Shi PA. Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis. Am J Hematol. 2015 May;90(5):381-5. doi: 10.1002/ajh.23956. Epub 2015 Apr 1."
                },
                {
                    "pmid": "32951731",
                    "type": "RESULT",
                    "citation": "Manwani D, Xu C, Lee SK, Amatuni G, Cohen HW, Carullo V, Morrone K, Davila J, Shi PA, Ireland K, Keenan J, Frenette PS. Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis. Complement Ther Med. 2020 Aug;52:102481. doi: 10.1016/j.ctim.2020.102481. Epub 2020 Jun 9."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000755",
                    "term": "Anemia, Sickle Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000745",
                    "term": "Anemia, Hemolytic, Congenital"
                },
                {
                    "id": "D000000743",
                    "term": "Anemia, Hemolytic"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006453",
                    "term": "Hemoglobinopathies"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4085",
                    "name": "Anemia, Sickle Cell",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M29525",
                    "name": "Acute Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "relevance": "LOW"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M4073",
                    "name": "Anemia, Hemolytic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4075",
                    "name": "Anemia, Hemolytic, Congenital",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9539",
                    "name": "Hemoglobinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T5229",
                    "name": "Sickle Cell Anemia",
                    "asFound": "Sickle Cell Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007136",
                    "term": "Immunoglobulins"
                },
                {
                    "id": "D000000906",
                    "term": "Antibodies"
                },
                {
                    "id": "D000005719",
                    "term": "gamma-Globulins"
                },
                {
                    "id": "D000016756",
                    "term": "Immunoglobulins, Intravenous"
                },
                {
                    "id": "D000018029",
                    "term": "Rho(D) Immune Globulin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "asFound": "Separate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "asFound": "Separate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "asFound": "Intervention Trial",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8836",
                    "name": "gamma-Globulins",
                    "asFound": "Intervention Trial",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20191",
                    "name": "Rho(D) Immune Globulin",
                    "asFound": "Intervention Trial",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}